Published in Ther Drug Monit on April 01, 2001
Pilot Trial for Implementation of a MPA PK Monitoring Strategy (MPA) | NCT00187915
Characterizing the role of enterohepatic recycling in the interactions between mycophenolate mofetil and calcineurin inhibitors in renal transplant patients by pharmacokinetic modelling. Br J Clin Pharmacol (2005) 1.06
Mycophenolate pharmacokinetics and association with response to acute graft-versus-host disease treatment from the Blood and Marrow Transplant Clinical Trials Network. Biol Blood Marrow Transplant (2010) 1.03
Population pharmacokinetic analysis of mycophenolic acid in renal transplant recipients following oral administration of mycophenolate mofetil. Br J Clin Pharmacol (2003) 0.95
Population pharmacokinetics and dose optimization of mycophenolic acid in HCT recipients receiving oral mycophenolate mofetil. J Clin Pharmacol (2013) 0.93
Effect of uptake transporters OAT3 and OATP1B1 and efflux transporter MRP2 on the pharmacokinetics of eluxadoline. J Clin Pharmacol (2015) 0.93
Pharmacokinetic role of protein binding of mycophenolic acid and its glucuronide metabolite in renal transplant recipients. J Pharmacokinet Pharmacodyn (2009) 0.91
Population pharmacokinetics of mycophenolic acid during the first week after renal transplantation. Eur J Clin Pharmacol (2005) 0.91
Time-dependent clearance of mycophenolic acid in renal transplant recipients. Br J Clin Pharmacol (2007) 0.88
Impact of UGT1A9 Polymorphism on Mycophenolic Acid Pharmacokinetic Parameters in Stable Renal Transplant Patients. Iran J Pharm Res (2013) 0.87
Population pharmacokinetics of unbound mycophenolic acid in adult allogeneic haematopoietic cell transplantation: effect of pharmacogenetic factors. Br J Clin Pharmacol (2013) 0.87
Risk of diarrhoea in a long-term cohort of renal transplant patients given mycophenolate mofetil: the significant role of the UGT1A8 2 variant allele. Br J Clin Pharmacol (2010) 0.86
Pharmacokinetic and pharmacodynamic analysis of enteric-coated mycophenolate sodium: limited sampling strategies and clinical outcome in renal transplant patients. Br J Clin Pharmacol (2010) 0.86
Mycophenolic acid pharmacokinetics and related outcomes early after renal transplant. Br J Clin Pharmacol (2005) 0.85
Effects of gastric emptying on oral mycophenolic acid pharmacokinetics in stable renal allograft recipients. Br J Clin Pharmacol (2006) 0.84
Population pharmacokinetics and Bayesian estimator of mycophenolic acid in children with idiopathic nephrotic syndrome. Br J Clin Pharmacol (2010) 0.84
Long-term follow-up of a phase III clinical trial comparing tacrolimus extended-release/MMF, tacrolimus/MMF, and cyclosporine/MMF in de novo kidney transplant recipients. Transplantation (2014) 0.83
Pharmacokinetic optimization of immunosuppressive therapy in thoracic transplantation: part I. Clin Pharmacokinet (2009) 0.83
Population pharmacokinetics of mycophenolic acid in children and young people undergoing blood or marrow and solid organ transplantation. Br J Clin Pharmacol (2010) 0.82
Impact of changing from cyclosporine to tacrolimus on pharmacokinetics of mycophenolic acid in renal transplant recipients with diabetes. Ther Drug Monit (2008) 0.82
Total and free mycophenolic acid and its 7-O-glucuronide metabolite in Chinese adult renal transplant patients: pharmacokinetics and application of limited sampling strategies. Eur J Clin Pharmacol (2006) 0.81
Prospective randomized trial of maintenance immunosuppression with rapid discontinuation of prednisone in adult kidney transplantation. Am J Transplant (2013) 0.80
Inosine monophosphate dehydrogenase variability in renal transplant patients on long-term mycophenolate mofetil therapy. Br J Clin Pharmacol (2010) 0.79
Performance of the new mycophenolate assay based on IMPDH enzymatic activity for pharmacokinetic investigations and setup of Bayesian estimators in different populations of allograft recipients. Ther Drug Monit (2009) 0.78
Immunosuppression for in vivo research: state-of-the-art protocols and experimental approaches. Cell Mol Immunol (2016) 0.77
Influence of sex and race on mycophenolic acid pharmacokinetics in stable African American and Caucasian renal transplant recipients. Clin Pharmacokinet (2015) 0.77
Clinical mycophenolic acid monitoring in liver transplant recipients. World J Gastroenterol (2014) 0.76
Mycophenolate pharmacokinetics and pharmacodynamics in belatacept treated renal allograft recipients - a pilot study. J Transl Med (2009) 0.76
The transplanted child: New immunosuppressive agents and the need for pharmacokinetic monitoring. Paediatr Child Health (2002) 0.76
Late Conversion of Kidney Transplant Recipients from Ciclosporin to Tacrolimus Improves Graft Function: Results from a Randomized Controlled Trial. PLoS One (2015) 0.75
Does tacrolimus, in comparison with sirolimus, increase mycophenolic acid exposure in kidney transplant recipients? Clin Pharmacol Ther (2010) 0.75
Interplay of drug metabolizing enzymes with cellular transporters. Wien Med Wochenschr (2014) 0.75
Steady-state pharmacokinetics of mycophenolic acid in renal transplant patients: exploratory analysis of the effects of cyclosporine, recipients' and donors' ABCC2 gene variants, and their interactions. Eur J Clin Pharmacol (2017) 0.75
Pharmacokinetics and dynamics of mycophenolate mofetil after single-dose oral administration in juvenile dachshunds. J Vet Pharmacol Ther (2017) 0.75
A delicate balance between rejection and BK polyomavirus associated nephropathy; A retrospective cohort study in renal transplant recipients. PLoS One (2017) 0.75
Pharmacokinetics of mycophenolic acid in children with clinically stable idiopathic nephrotic syndrome receiving cyclosporine. Clin Exp Nephrol (2016) 0.75
Shigella infection of henle intestinal epithelial cells: role of the host cell. Infect Immun (1979) 5.09
Mediastinitis and cardiac surgery--an updated risk factor analysis in 10,373 consecutive adult patients. Thorac Cardiovasc Surg (2002) 2.81
The alpha 2-macroglobulin receptor/low density lipoprotein receptor-related protein binds and internalizes Pseudomonas exotoxin A. J Biol Chem (1992) 2.40
Altered surfactant function and structure in SP-A gene targeted mice. Proc Natl Acad Sci U S A (1996) 2.29
Receptor-mediated internalization of Pseudomonas toxin by mouse fibroblasts. Cell (1980) 2.17
The epidemiology of serious eye injuries from the United States Eye Injury Registry. Graefes Arch Clin Exp Ophthalmol (2000) 1.81
Mechanism of action for leflunomide in rheumatoid arthritis. Clin Immunol (1999) 1.72
Cytochrome P-450 3A enzymes are responsible for biotransformation of FK506 and rapamycin in man and rat. Drug Metab Dispos (1992) 1.59
Effects of cyclosporin, FK506, and rapamycin on graft-vessel disease. Lancet (1991) 1.49
In vitro and in vivo activity and cross resistance profiles of novel ruthenium (II) organometallic arene complexes in human ovarian cancer. Br J Cancer (2002) 1.45
Newer immunosuppressive drugs: a review. J Am Soc Nephrol (1999) 1.43
Protein kinase C inhibitor sotrastaurin in de novo liver transplant recipients: a randomized phase II trial. Am J Transplant (2015) 1.40
Lactonization is the critical first step in the disposition of the 3-hydroxy-3-methylglutaryl-CoA reductase inhibitor atorvastatin. Drug Metab Dispos (2000) 1.40
Metabolism of the immunosuppressant tacrolimus in the small intestine: cytochrome P450, drug interactions, and interindividual variability. Drug Metab Dispos (1995) 1.39
The transforming growth factor-betas. A new family of immunoregulatory molecules. Ann N Y Acad Sci (1990) 1.36
Cell cycle protein expression in vascular smooth muscle cells in vitro and in vivo is regulated through phosphatidylinositol 3-kinase and mammalian target of rapamycin. Arterioscler Thromb Vasc Biol (2001) 1.36
Receptor-mediated entry of diphtheria toxin into monkey kidney (Vero) cells: electron microscopic evaluation. Infect Immun (1985) 1.36
Evolving techniques in the treatment of macular detachment caused by optic nerve pits. Ophthalmology (1988) 1.32
mTOR inhibitors: an overview. Liver Transpl (2001) 1.32
AnkB, a periplasmic ankyrin-like protein in Pseudomonas aeruginosa, is required for optimal catalase B (KatB) activity and resistance to hydrogen peroxide. J Bacteriol (2000) 1.31
Molecular mechanisms of action of new xenobiotic immunosuppressive drugs: tacrolimus (FK506), sirolimus (rapamycin), mycophenolate mofetil and leflunomide. Curr Opin Immunol (1996) 1.31
Consensus document: therapeutic monitoring of tacrolimus (FK-506). Ther Drug Monit (1995) 1.30
Rapamycin reverses chronic graft vascular disease in a novel cardiac allograft model. Circulation (1999) 1.30
Immunoregulatory role of transforming growth factor beta (TGF-beta) in development of killer cells: comparison of active and latent TGF-beta 1. J Exp Med (1990) 1.28
Rapamycin inhibits arterial intimal thickening caused by both alloimmune and mechanical injury. Its effect on cellular, growth factor, and cytokine response in injured vessels. Transplantation (1993) 1.22
Globe perforation from peribulbar injection. Arch Ophthalmol (1987) 1.17
Receptor-mediated entry of Pseudomonas toxin: methylamine blocks clustering step. Infect Immun (1983) 1.15
Impact of diabetes mellitus on cardiac surgery outcome. Thorac Cardiovasc Surg (2003) 1.14
Stanford experience with obliterative bronchiolitis after lung and heart-lung transplantation. Ann Thorac Surg (1996) 1.10
The pharmacokinetics and metabolic disposition of tacrolimus: a comparison across ethnic groups. Clin Pharmacol Ther (2001) 1.09
Regulation of the macrophage vacuolar ATPase and phagosome-lysosome fusion by Histoplasma capsulatum. J Immunol (1999) 1.07
Localization of ClC-2 Cl- channels in rabbit gastric mucosa. Am J Physiol Cell Physiol (2001) 1.06
The role of respiratory epithelium in a rat model of obliterative airway disease. Transplantation (2000) 1.06
In vitro evaluation of the disposition of A novel cysteine protease inhibitor. Drug Metab Dispos (2000) 1.06
Comparison of the in vitro metabolism of the macrolide immunosuppressants sirolimus and RAD. Transplant Proc (2001) 1.06
Vitrectomy in asteroid hyalosis. Retina (1990) 1.05
Dental caries experience of disabled children and young adults in Kuwait. Community Dent Health (2001) 1.04
Sensitive and specific quantification of sirolimus (rapamycin) and its metabolites in blood of kidney graft recipients by HPLC/electrospray-mass spectrometry. Clin Chem (1996) 1.02
Prognostic factors in patients with differentiated thyroid carcinoma. Eur J Surg (2000) 1.02
Therapeutic monitoring of mycophenolic acid. A consensus panel report. Clin Biochem (1998) 1.01
Histoplasma capsulatum yeasts are phagocytosed via very late antigen-5, killed, and processed for antigen presentation by human dendritic cells. J Immunol (2001) 1.00
Technics for fiberoptic laryngoscopy in anesthesia. Anesth Analg (1974) 1.00
Binding and uptake of pulmonary surfactant protein (SP-A) by pulmonary type II epithelial cells. J Histochem Cytochem (1989) 1.00
Metabolism and transport of the macrolide immunosuppressant sirolimus in the small intestine. J Pharmacol Exp Ther (1998) 1.00
Reduced temperature alters Pseudomonas exotoxin A entry into the mouse LM cell. Infect Immun (1986) 1.00
Differential effects of glucocorticoid on expression of surfactant proteins in a human lung adenocarcinoma cell line. Biochim Biophys Acta (1988) 0.99
Grapefruit juice activates P-glycoprotein-mediated drug transport. Pharm Res (1999) 0.99
Comparison of cytochrome P-450-dependent metabolism and drug interactions of the 3-hydroxy-3-methylglutaryl-CoA reductase inhibitors lovastatin and pravastatin in the liver. Drug Metab Dispos (1999) 0.98
Sirolimus, but not the structurally related RAD (everolimus), enhances the negative effects of cyclosporine on mitochondrial metabolism in the rat brain. Br J Pharmacol (2001) 0.98
Association of down-regulation of cytokine activity with rat hind limb allograft survival. Transplantation (1995) 0.97
Evidence for pseudomonas exotoxin A receptors on plasma membrane of toxin-sensitive lm fibroblasts. Infect Immun (1984) 0.97
Normal surfactant pool sizes and inhibition-resistant surfactant from mice that overexpress surfactant protein A. Am J Respir Cell Mol Biol (1999) 0.96
Isolation and characterization of Pseudomonas aeruginosa exotoxin A binding glycoprotein from mouse LM cells. J Biol Chem (1991) 0.96
Treatment with rapamycin and mycophenolic acid reduces arterial intimal thickening produced by mechanical injury and allows endothelial replacement. Transplantation (1995) 0.96
Time-dependent effects of imatinib in human leukaemia cells: a kinetic NMR-profiling study. Br J Cancer (2009) 0.95
Accumulation of lovastatin, but not pravastatin, in the blood of cyclosporine-treated kidney graft patients after multiple doses. Clin Pharmacol Ther (1997) 0.95
Immunosuppressants: cellular and molecular mechanisms of action. Am J Kidney Dis (1996) 0.94
Visualization of intracellular trafficking: use of biotinylated ligands in conjunction with avidin-gold colloids. J Histochem Cytochem (1984) 0.92
Right hepatic lobectomy for recurrent cholangitis after combined bile duct and right hepatic artery injury during laparoscopic cholecystectomy: a report of two cases. Langenbecks Arch Surg (2002) 0.92
Effects of humanized monoclonal antibody to rhesus CD11a in rhesus monkey cardiac allograft recipients. Transplantation (2000) 0.92
Ocular self-mutilation. Ann Ophthalmol (1989) 0.92
Active transport of the angiotensin-II antagonist losartan and its main metabolite EXP 3174 across MDCK-MDR1 and caco-2 cell monolayers. Br J Pharmacol (2000) 0.91
Sotrastaurin, a novel small molecule inhibiting protein kinase C: first clinical results in renal-transplant recipients. Am J Transplant (2010) 0.91
Essential role of calcium in cellular internalization of Pseudomonas toxin. Infect Immun (1982) 0.91
Evaluation of the effects of immunosuppressants on neuronal and glial cells in vitro by multinuclear magnetic resonance spectroscopy. Biochim Biophys Acta (1996) 0.90
A novel mechanism of action of the immunomodulatory drug, leflunomide: augmentation of the immunosuppressive cytokine, TGF-beta 1, and suppression of the immunostimulatory cytokine, IL-2. Transplant Proc (1996) 0.90
Diphtheria toxin does not enter resistant cells by receptor-mediated endocytosis. Infect Immun (1983) 0.90
Flow cytometric quantitation of calcium-dependent and -independent mitogen-stimulation of T cell functions in whole blood: inhibition by immunosuppressive drugs in vitro. J Immunol Methods (2001) 0.90
Immortalization of subpopulations of respiratory epithelial cells from transgenic mice bearing SV40 large T antigen. Am J Physiol (1994) 0.90
Efficacy of sotrastaurin plus tacrolimus after de novo kidney transplantation: randomized, phase II trial results. Am J Transplant (2013) 0.90
Leflunomide and malononitriloamides. Expert Opin Investig Drugs (1997) 0.89
Sotrastaurin in calcineurin inhibitor-free regimen using everolimus in de novo kidney transplant recipients. Am J Transplant (2013) 0.89
Effects of treatment with cyclosporine, FK 506, rapamycin, mycophenolic acid, or deoxyspergualin on vascular muscle proliferation in vitro and in vivo. Transplant Proc (1993) 0.89
An ex vivo model to study the intestinal biotransformation of immunosuppressives. Transplant Proc (2000) 0.88
Pharmacodynamics of immunosuppression by mycophenolic acid: inhibition of both lymphocyte proliferation and activation correlates with pharmacokinetics. J Pharmacol Exp Ther (1999) 0.88
Vascular endothelial growth factor in the rat pituitary: differential distribution and regulation by estrogen. J Endocrinol (2000) 0.88
Prevention of neointimal proliferation by immunosuppression in synthetic vascular grafts. Eur J Cardiothorac Surg (2001) 0.88
Pirfenidone: A novel anti-fibrotic agent and progressive chronic allograft rejection. Pulm Pharmacol Ther (2002) 0.87
A dermoid cyst in the greater omentum as a rare epigastric tumor. Z Gastroenterol (2004) 0.87
Epithelial re-growth is associated with inhibition of obliterative airway disease in orthotopic tracheal allografts in non-immunosuppressed rats. Transplantation (2000) 0.87
Metabolism of the macrolide immunosuppressant, tacrolimus, by the pig gut mucosa in the Ussing chamber. Br J Pharmacol (1996) 0.87
Recovery of vision after presumed direct optic nerve injury. Ophthalmology (1987) 0.86
Use of nondepolarizing anesthetic agents in penetrating ocular injuries. Anesthesiology (1986) 0.86
Graft-versus-host disease prevention by rapamycin: cellular mechanisms. Biol Blood Marrow Transplant (2000) 0.86
Primary immunosuppression with tacrolimus after liver transplantation: 12-years follow-up. Int Immunopharmacol (2005) 0.86
Diltiazem increases blood concentrations of cyclized cyclosporine metabolites resulting in different cyclosporine metabolite patterns in stable male and female renal allograft recipients. Br J Clin Pharmacol (1996) 0.85
Azurophilic granules of human neutrophils contain CD14. Infect Immun (1997) 0.85
Effect of splenectomy and mono- or combination therapy with rapamycin, the morpholinoethyl ester of mycophenolic acid and deoxyspergualin on cardiac xenograft survival. Transplant Proc (1991) 0.85
Diabetes in patients undergoing coronary artery bypass grafting. Impact on perioperative outcome. Z Kardiol (2005) 0.85
The therapeutic prescription for the organ transplant recipient: the linkage of immunosuppression and antimicrobial strategies. Transpl Infect Dis (1999) 0.85
Inhibition of cellular protein synthesis by vaccinia virus surface tubules. Virology (1982) 0.85
Rapamycin and p53 act on different pathways to induce G1 arrest in mammalian cells. Oncogene (1997) 0.85
T cell subsets required for protection against age-dependent polioencephalomyelitis of C58 mice. J Immunol (1982) 0.85
Immunosuppressive therapies for the prevention and treatment of obliterative airway disease in heterotopic rat trachea allografts. Transplantation (2000) 0.85
Pitfalls in monitoring tacrolimus (FK 506). Ther Drug Monit (1997) 0.85
Comparison of the immunosuppressive and toxic effects of FK506 and cyclosporine in xenograft recipients. Transplant Proc (1989) 0.85
Endoscopic surgery vs temporary keratoprosthesis vitrectomy. Arch Ophthalmol (1991) 0.85
The novel immunosuppressant SDZ-RAD protects rat brain slices from cyclosporine-induced reduction of high-energy phosphates. Br J Pharmacol (2000) 0.85